Clinical trials: Alzheimer's
Healthy Elderly
MAD Study of NX210c
This study will investigate the safety and tolerability of multiple intravenous infusions of NX210c with two ascending doses as well as NX210c pharmacokinetics (PK), and pharmacodynamics (PD) effects in healthy elderly subjects.
- Trial name
- CHDR2235 (NCT05827653)
- Testing
- NX210c
- Where
- Netherlands
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Axoltis Pharma
Alzheimer's Disease
Memantine and Validation of a New Alzheimer's Disease Scale
To validate a new Alzheimer's Disease scale against other rating tools in subjects with dementia of Alzheimer's type, treated with memantine.
- Trial name
- NCT00804271
- Testing
- memantine
- Where
- Germany
- Volunteers
- 487 people
- Sponsor
- Merz Pharmaceuticals GmbH
Dementia of the Alzheimer's Type
Long Term Extension Safety Study in Patients With Dementia of the Alzheimer's Type Who Completed Study CPC-001-07
This is a long-term-safety roll-over extension study for a Phase II Study (Protocol CPC-001-07).
- Trial name
- NCT02434666
- Testing
- CPC-201
- Where
- 5 sites in United States
- Volunteers
- 21 people
- Sponsor
- Chase Pharmaceuticals Corporation, an affiliate of Allergan plc
Alzheimer Disease, Dementia
A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)
The main goals of this study are to further determine whether the study drug donanemab is safe and effective in participants with Alzheimer's disease and to validate neuropsychological assessments administered over…
- Conditions
- Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases
- Trial name
- NCT04640077
- Testing
- No Intervention, donanemab
- Where
- 27 sites in United States, Canada
- Volunteers
- 95 people
- Sponsor
- Eli Lilly and Company
Alzheimer's Disease
A Study to Evaluate the Effects of Itraconazole on MK-1708 in Healthy Participants (MK-1708-003)
The goal of the study is to see what happens to levels of MK-1708 a person's body over time. Researchers will compare what happens to MK-1708 in the body when it is given with or without a medicine called itraconazole.
- Trial name
- NCT06586606
- Testing
- MK-1708, Itraconazole
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Alzheimer's Disease
Study of Memantine in Assessment of Selected Measures of Volumetric Magnetic Resonance Imaging (MRI) and Cognition in Moderate AD (Alzheimer's Disease)
The purpose of this study is to characterize the progression of disease using volumetric MRI techniques and cognitive outcome measures in patients with moderate dementia of the Alzheimer's type treated with open-label memantine.
- Trial name
- NCT00334906
- Testing
- memantine HCl
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Forest Laboratories
Alzheimer's Disease, Blood Brain Barrier
Pilot Clinical Trial to Assess the Safety of NMS-01 in Patients With Mild to Moderate Alzheimer's Disease
A single-center, single-arm, prospective, open-label, pilot clinical trial to evaluate the safety and efficacy of the Focused ultrasound stimulator system (NMS-01) for transient Blood-Brain Barrier (BBB) opening in patients with…
- Trial name
- NMSBBBOYUSH01 (NCT07869238)
- Testing
- NMS-01
- Where
- South Korea
- Volunteers
- 10 people
- Sponsor
- Neumous Inc.
Alzheimer's Disease, Vascular Dementia
Seroquel- Agitation Associated With Dementia
The purpose of this study is to determine how safe and effective Seroquel (quetiapine fumarate) is compared to placebo (a non-drug tablet) for a period of up to 10 weeks in the treatment of agitation symptoms in nursing home or…
- Trial name
- NCT00621647
- Testing
- Quetiapine Fumarate
- Volunteers
- 333 people
- Sponsor
- AstraZeneca
Alzheimer's Disease
Imaging Characteristics of a Follow-up 18F-AV-1451 Scan
This study will evaluate the imaging characteristics of flortaucipir in subjects with a previous flortaucipir scan in order to assess the rate of change of tau deposition over time.
- Trial name
- NCT02051764
- Testing
- Flortaucipir F18, Florbetapir F 18, Brain PET Scan
- Where
- 4 sites in United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Alzheimer Disease, Healthy Volunteers
A Study of LY2886721 in Healthy Participants and Participants Diagnosed With Alzheimer's Disease
This study is being done for the following reasons: To determine the safety of LY2886721 and any side effects that may be associated with it and to see how much of the study drug is in the blood and the cerebrospinal fluid (CSF)…
- Trial name
- NCT01807026
- Testing
- LY2886721
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Alzheimer's Disease, Huntington Disease
A Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine)
This study will evaluate four different modified release formulation to estimate the amount of dimebon available to the body relative to the current dimebon formulation that is given three times a day.
- Trial name
- NCT00988624
- Testing
- Dimebon IR Tablet, Dimebon MR1, Dimebon MR2
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Pfizer
Alzheimer's Disease
A Multiple Ascending Dose Study of BPN14770 in Healthy Young and Elderly Male or Female Subjects
This is a randomized, double-blind (Investigator and subject-blinded) placebo-controlled, multiple, ascending-dose study to evaluate the safety, tolerability, and pharmacokinetic profile of BPN14770 in healthy young and elderly…
- Trial name
- NCT02840279
- Testing
- BPN14770
- Where
- United States
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Tetra Discovery Partners
Alzheimer's Dementia
Phase 3 Clinical Trial of Wujia Yizhi Granules in the Treatment of Mild-to-moderate Alzheimer's Dementia (Syndrome of Deficiency of Spleen and Kidney)
This study is a randomized, double-blind, placebo-controlled phase 3 design aimed at further verifying the safety and efficacy of Wujia Yizhi granules for mild-to-moderate Alzheimer's dementia
- Trial name
- NCT06534723
- Testing
- Wujia Yizhi granules
- Where
- China
- Volunteers
- 570 people
- Sponsor
- Sichuan Jishengtang Pharmaceutical Co., Ltd.
Alzheimer Disease
Study in Subjects With Mild-to-Moderate Alzheimer's Dementia
ALZN002-01 is a first-in-human, randomized, double-blind, placebo-controlled, parallel-group, phase 1/2a study of autologous amyloid beta mutant peptide-pulsed dendritic cells (ALZN002) in subjects with mild-to-moderate dementia…
- Trial name
- NCT05834296
- Testing
- ALZN002 (autologous DCs pulsed with E22W mutant peptide).
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Alzamend Neuro, Inc.
Mild Cognitive Impairment (MCI) Amnestic, Parkinson Disease (PD)
Early Stage of Alzheimer's and Parkinson's Diseases, HearIng Relevance (SAPHIR)
The study aims to phenotype hearing in patients with early stage of neurodegenerative disorders to explore the prevalence of various hearing disorders in comparison to a control population.
- Conditions
- Mild Cognitive Impairment (MCI) Amnestic, Parkinson Disease (PD), Healthy Participants
- Trial name
- SAPHIR (NCT07083089)
- Testing
- Thorough Hearing assessment
- Where
- 4 sites in France
- Volunteers
- 309 people, healthy volunteers welcome
- Sponsor
- Cilcare SAS
Alzheimer's Disease
Efficacy and Safety of MK-1942 as an Adjunct Therapy in Participants With Mild to Moderate Alzheimer's Disease Dementia (MK-1942-008)
The main purpose of this study was to assess the safety and efficacy of MK-1942 as adjunctive therapy in participants with mild to moderate Alzheimer's Disease (AD) dementia.
- Trial name
- NCT05602727
- Testing
- MK-1942
- Where
- 74 sites in United States, Argentina and 9 more
- Volunteers
- 99 people
- Sponsor
- Merck Sharp & Dohme LLC
Mild Cognitive Impairment (MCI), Early Stages of Cognitive Decline
Mild Cognitive Impairment Community Screening and Early Intervention Via Stem Cell Therapy and Wearable Brain Computer Interface Device.
This study aims to evaluate the efficacy of community-based early detection and targeted interventions, including stem cell therapy and wearable non-invasive brain-computer interface (BCI) devices, for Mild Cognitive Impairment…
- Conditions
- Mild Cognitive Impairment (MCI), Early Stages of Cognitive Decline, Alzheimer's Disease Dementia, Alzheimer's Disease Diagnosis
- Trial name
- MCITestCare (NCT07214974)
- Testing
- Structured wellness care, Wearable brain-computer interface devices, Stem Cell Therapy - Experimental
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Noah Tech, Corp.
Alzheimer's Disease
A 24 Week, Multicenter, Open, Evaluation of the Clinical Effectiveness of the Once-daily 10 cm^2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (EXTRA)
This study is designed to confirm the efficacy, the tolerability, the patient compliance and the caregiver satisfaction with rivastigmine target patch size 10 cm^2 in patients with probable Alzheimer's Disease (Mini-Mental State…
- Trial name
- EXTRA (NCT00622713)
- Testing
- Rivastigmine transdermal patch
- Where
- France
- Volunteers
- 228 people
- Sponsor
- Novartis
Alzheimer's Disease
Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Subjects and an Elderly Cohort
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of E2609 when administered as single doses to healthy adult volunteers and healthy elderly subjects.
- Trial name
- NCT01294540
- Testing
- Drug: E2609
- Where
- United States
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Alzheimer Disease
BI 425809 in Patients With Cognitive Impairment Due to Alzheimer's Disease.
The study is designed to compare the effects of BI 425809 compared to placebo in patients with cognitive impairment due to Alzheimer's Disease.
- Trial name
- NCT02788513
- Testing
- BI 425809 dose 1, BI 425809 dose 2, BI 425809 dose 3
- Where
- 95 sites in United States, Austria and 12 more
- Volunteers
- 611 people
- Sponsor
- Boehringer Ingelheim